A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN)
2019
European Journal of Cancer
Preserved Fulltext
Coagulation activation is a hallmark of cancer, and anticoagulants have shown tumour-inhibiting properties. However, recent trials have failed to demonstrate improved survival with low-molecular-weight heparin (LMWH) in cancer populations. This has raised the question of suboptimal adherence as a possible explanation for the lack of benefit. Still, there is no standardised method to directly monitor LMWH in patient plasma. Here, we directly determine LMWH levels in patients using the Heparin
doi:10.1016/j.ejca.2019.06.015
pmid:31326730
fatcat:tqjluclgkbaebpsxqm3qh2lfau